Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment
Study Details
Study Description
Brief Summary
Primary Objective:
- To assess potential impact of moderate and severe renal impairment on the pharmacokinetics of cabazitaxel
Secondary Objective:
- To assess the safety of cabazitaxel in patients with various degrees of renal impairment
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
The study consists of a screening phase, registration, cabazitaxel administration will start within 5 business days of registration, with 21-day study treatment cycles. Cycle lengths may be extended up to a maximum of 14 additional days in case of unresolved toxicity. Patients continue to receive treatment until they experience, unacceptable toxicities/Adverse Events, disease progression, withdraw their consent, or the investigator decides to discontinue the patient, and the subsequent 30 days follow-up or study cut-off, whichever comes first.
Patients may continue to be treated as long as they are benefiting from study treatment and have not met study withdrawn criteria.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort A Normal renal function - Cabazitaxel administered once every 3 weeks |
Drug: Cabazitaxel XRP6258
Pharmaceutical form: solution for infusion Route of administration: intravenous
|
| Experimental: Cohort B Moderate renal dysfunction - Cabazitaxel administered once every 3 weeks |
Drug: Cabazitaxel XRP6258
Pharmaceutical form: solution for infusion Route of administration: intravenous
|
| Experimental: Cohort C Severe renal dysfunction - Cabazitaxel administered once every 3 weeks |
Drug: Cabazitaxel XRP6258
Pharmaceutical form: solution for infusion Route of administration: intravenous
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetic profile of cabazitaxel in study population [Up to day 10]
Secondary Outcome Measures
- Safety profile of cabazitaxel in study population, as measured by adverse events, clinical, laboratory and ECG parameters [up to 30 days after the last dosing]
Eligibility Criteria
Criteria
Inclusion criteria :
-
Diagnosis of histologically or cytologically proven non-hematologic malignancy. The cancer must be one that is either refractory to standard therapy or for which no standard therapy exists. Cabazitaxel is an adequate treatment option, as judged by investigator.
-
Eastern Cooperative Oncology Group performance status 0 - 2
-
Stable renal function
-
Patients must have adequate liver and marrow function as defined below:
-
Absolute neutrophil count ≥ 1.5x10^9/L
-
Platelets ≥ 100x10^9/L
-
Total bilirubin ≤ 1.0 x the institutions upper limit of normal
-
AST (SGOT)/ALT (SGPT) ≤ 2.5 x the institutions upper limit of normal
-
Alkaline phosphatase ≤ 2.5 x the institutions upper limit of normal
-
Patient may have a Grade 1 or less neurotoxicity at study entry.
-
Life expectancy > 3 months
-
Age ≥ 18 years old
-
If female, subject must use a double contraception method, except if she is sterilized for more than 3 months or postmenopausal.
-
Having given written informed consent prior to any procedure related to the study
Exclusion criteria:
-
Less than 4 weeks have elapsed from prior anticancer therapy (surgery, chemotherapy, radiation therapy, hormonal therapy and immunotherapy). Prior isotope therapy and radiotherapy to ≥ 30% of bone marrow are not allowed.
-
Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, class III or IV congestive heart failure, stroke or transient ischemic attack.
-
Any of the following within 3 months prior to study start: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
-
Active hepatitis
-
Acute renal failure (new or superimposed to pre-existing chronic renal impairment), nephrotic syndrome.
-
Patients requiring dialysis during the study.
-
History of hypersensitivity to docetaxel or polysorbate 80.
-
Known acquired immunodeficiency syndrome (AIDS-related illnesses) or known HIV disease requiring antiretroviral treatment.
-
Known brain metastases.
-
If female, pregnancy or breast-feeding.
-
Any treatment known to induce CYP isoenzymes (e.g., phenobarbital, phenytoin, carbamazepine, rifampicin, St John's Wort) or to strongly inhibit CYP3A4 activities (e.g., ketoconazole, itraconazole, macrolides, antiprotease agents, etc) is not allowed within 2 weeks before or during the test period of the pharmacokinetic sampling
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Investigational Site Number 056002 | Bruxelles | Belgium | 1200 | |
| 2 | Investigational Site Number 056001 | Gent | Belgium | 9000 | |
| 3 | Investigational Site Number 380001 | Milano | Italy | 20133 | |
| 4 | Investigational Site Number 528001 | Rotterdam | Netherlands | 3075 EA | |
| 5 | Investigational Site Number 528002 | Utrecht | Netherlands | 3584 CX | |
| 6 | Investigational Site Number 724001 | Barcelona | Spain | 08035 | |
| 7 | Investigational Site Number 826001 | Cambridge | United Kingdom | CB2 2QQ |
Sponsors and Collaborators
- Sanofi
Investigators
- Study Director: Clinical Sciences & Operations, Sanofi
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- POP12251
- 2011-001517-14
- U1111-1121-4512